CCR2 antibody

Catalog No. ABIN2664331

The Mouse Monoclonal anti-CCR2 antibody has been validated for ICFC. It is suitable to detect CCR2 in samples from Human.

Quick Overview for CCR2 antibody (ABIN2664331)

Target: CCR2 (Chemokine (C-C Motif) Receptor 2 (CCR2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CCR2 antibody is un-conjugated

Application: Intracellular Flow Cytometry (ICFC)

Clone: K036C2

Product Details anti-CCR2 Antibody

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CCR2

Target: CCR2 (Chemokine (C-C Motif) Receptor 2 (CCR2))

Alternative Name: CD192

Background: CCR2 is a chemokine receptor that binds monocyte chemoattractant proteins (MCP-1, 2, 3 and 4). Two spliced variants were initially described for CCR2 (CCR2A and CCR2B). These variants differ in their terminal carboxyl tails. Monocyte adhesion to the arterial endothelium and subsequent migration into the intima are central events in the pathogenesis of atherosclerosis. CCR2 and MCP-1 have been associated to atherosclerotic plaques. MCP-1 is induced by modified-LDL in endothelial cells and may trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Local overexpression of MCP-1 at vessel walls induces infiltration of macrophages and formation of atherosclerotic lesions. Obesity induces an inflammatory state that is implicated in many clinically important complications, including insulin resistance, diabetes, atherosclerosis, and non-alcoholic fatty liver disease. CCR2 influences the development of obesity and associated adipose tissue inflammation.

Pathways: cAMP Metabolic Process, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process